Maria Krevvata

2.5k total citations
23 papers, 479 citations indexed

About

Maria Krevvata is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Maria Krevvata has authored 23 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Maria Krevvata's work include Multiple Myeloma Research and Treatments (20 papers), Peptidase Inhibition and Analysis (8 papers) and Protein Degradation and Inhibitors (7 papers). Maria Krevvata is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Peptidase Inhibition and Analysis (8 papers) and Protein Degradation and Inhibitors (7 papers). Maria Krevvata collaborates with scholars based in United States, Spain and Canada. Maria Krevvata's co-authors include Kihyun Kım, Sonali Trivedi, Jon Ukropec, Ming Qi, P. Joy Ho, Darrell White, Nizar J. Bahlis, Philippe Moreau, Jesús F. San Miguel and Naoki Takezako and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Maria Krevvata

21 papers receiving 472 citations

Peers

Maria Krevvata
Comparison fields: 5 of 37
  • Hematology 422
  • Molecular Biology 288
  • Oncology 263
  • Immunology 72
  • Genetics 66
Replace Joan Bladé with:
Joan Bladé Spain
Luis Palomera Spain
Yoshiaki Kuroda Japan
María-Ángeles Montalbán Spain
Laura Montejano Spain
Raquel Jiménez Spain
Cara A. Rosenbaum United States
Mihaela Popa McKiver United States
K. Elias Germany
Jainulabdeen J. Ifthikharuddin United States
Joan Bladé Spain View profile →
Citations per field, relative to Maria Krevvata
Maria Krevvata · 1×
Citations per year, relative to Maria Krevvata
Maria Krevvata · 1×

Countries citing papers authored by Maria Krevvata

Since Specialization
Citations

This map shows the geographic impact of Maria Krevvata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Krevvata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Krevvata more than expected).

Fields of papers citing papers by Maria Krevvata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Krevvata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Krevvata. The network helps show where Maria Krevvata may publish in the future.

Co-authorship network of co-authors of Maria Krevvata

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Krevvata. A scholar is included among the top collaborators of Maria Krevvata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Krevvata. Maria Krevvata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
POSTER: MM-739 Daratumumab + Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) vs VRd in Transplant-Ineligible (TIE)/Transplant-Deferred (TD) Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 CEPHEUS Trial Cytogenetic Subgroup Analysis
2025 ·Clinical Lymphoma Myeloma & Leukemia ·Saad Z. Usmani, Nizar J. Bahlis, Thierry Façon, Sonja Zweegman, Christopher P. Venner, Marc Braunstein, Luděk Pour, Josep Martí, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legieć, Ângelo Maiolino, (unknown), Maria Krevvata, (unknown), Vânia Hungria
0
2
Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
2024 ·Blood ·(unknown), Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, (unknown), Andrew J. Cowan, (unknown), Sarah M. Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, (unknown), Maria Krevvata, Huiling Pei, Sharmila Patel, (unknown), Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
1
3
POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt, Michaël Sébag, Kihyun Kım, Chang‐Ki Min, Albert Oriol, Enrique M. Ocio, Sung‐Soo Yoon, María‐Victoria Mateos, Michael Chu, Paula Rodríguez‐Otero, Irit Avivi, Yue Guo, Maria Krevvata, Michelle Peterson, (unknown), Jill Vanak, Arnob Banerjee, Hila Magen
1
4
MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt, Michaël Sébag, Kihyun Kım, Chang‐Ki Min, Albert Oriol, Enrique M. Ocio, Sung‐Soo Yoon, María‐Victoria Mateos, Michael Chu, Paula Rodríguez‐Otero, Irit Avivi, Yue Guo, Maria Krevvata, Michelle Peterson, (unknown), Jill Vanak, Arnob Banerjee, Hila Magen
1
5
PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
2023 ·HemaSphere ·Ioannis V. Kostopoulos, Despina Fotiou, Maria Krevvata, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, (unknown), (unknown), (unknown), Nikolaos Kanellias, Magdalini Migkou, (unknown), Foteini Theodorakakou, Evangelos Terpos, Meletios Α. Dimopoulos, (unknown), Efstathios Kastritis
1
6
S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
2023 ·HemaSphere ·María‐Victoria Mateos, Daniel Morillo, Moshe E. Gatt, Michaël Sébag, Kihyun Kım, Chang‐Ki Min, Albert Oriol, Enrique M. Ocio, Sung‐Soo Yoon, Yaël C. Cohen, Michael Chu, Paula Rodríguez‐Otero, Irit Avivi, Yue Guo, Maria Krevvata, Michelle Peterson, (unknown), Jill Vanak, Arnob Banerjee, Hila Magen
5
7
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2023 ·Journal of Clinical Oncology ·Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt, Michaël Sébag, Kihyun Kım, Chang‐Ki Min, Albert Oriol, Enrique M. Ocio, Sung‐Soo Yoon, María‐Victoria Mateos, Michael Chu, Paula Rodríguez‐Otero, Irit Avivi, Yue Guo, Maria Krevvata, (unknown), (unknown), Jill Vanak, Arnob Banerjee, Hila Magen
58
8
Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples
2022 ·Blood ·Katherine Li, David R. Barnidge, Maria Krevvata, Mark Perkins, Raluca Verona, Enrique Zudaire
4
9
Abstract 1023: Understanding the anti-tumor activities of daratumumab in natural killer/T cell lymphoma (NKTCL)
2021 ·Cancer Research ·Tianyuan Zhou, Qing Min, Yann Abraham, Tatiana Perova, Cheryl Sweeney, Maria Krevvata
0
10
Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.
2021 ·Journal of Clinical Oncology ·Nina Shah, Sharmila Patel, Huiling Pei, Ming Qi, Maria Krevvata, Thomas S. Lin, (unknown)
3
11
Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes
2021 ·Blood ·Despina Fotiou, Ioannis V. Kostopoulos, Maria Krevvata, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, (unknown), (unknown), Panagiotis Malandrakis, Magdalini Migkou, Nikolaos Kanellias, (unknown), Foteini Theodorakakou, Evangelos Terpos, Ourania Tsitsilonis, Meletios Α. Dimopoulos, Efstathios Kastritis
2
12
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
2020 ·Leukemia ·Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, (unknown), Sonali Trivedi, Jon Ukropec, Ming Qi, Jesús F. San Miguel
158
13
Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor
2019 ·Blood ·Katja Weisel, Pieter Sonneveld, María‐Victoria Mateos, Vânia Hungria, Andrew Spencer, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Maria Krevvata, Sonali Trivedi, Xiang Qin, Huiling Pei, Jon Ukropec, Rachel Kobos, Ming Qi, Ajay K. Nooka
26
14
Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
2019 ·Blood ·Jonathan L. Kaufman, Saad Z. Usmani, Jesús F. San Miguel, Nizar J. Bahlis, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Maria Krevvata, Huiling Pei, Jon Ukropec, Thomas Renaud, Sonali Trivedi, Rachel Kobos, Meletios Α. Dimopoulos
28
15
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).
2019 ·Journal of Clinical Oncology ·Sonja Zweegman, Saad Z. Usmani, Katherine Chastain, Jodi Carey, (unknown), Elena Smith, Maria Krevvata, Jianping Wang, Jessica Vermeulen, Thierry Façon
26
16
Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)
2019 ·Blood ·Nikhil C. Munshi, Hervé Avet‐Loiseau, Kenneth C. Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Α. Dimopoulos, Margarita Kulakova, Bart Heeg, Mahmoud Hashim, Jon Ukropec, Kevin Liu, Maria Krevvata, Annette Lam, Sarah Côté, Nizar J. Bahlis
6
17
Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study
2019 ·Blood ·Nina Shah, Yana Lutska, Huiling Pei, Ming Qi, Maria Krevvata, Colleen Kane, Jon Ukropec, Thomas S. Lin, Shalaka Hampras
3
18
Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells
2018 ·Haematologica ·Maria Krevvata, Xiaochuan Shan, (unknown), Cédric Dos Santos, (unknown), Anthony Secreto, Joshua Glover, Winifred Trotman, (unknown), Selene Nuñez-Cruz, Gerald Wertheim, Hyun-Jeong Ra, Elizabeth A. Griffiths, (unknown), Gwenn Danet-Desnoyers, Martin Carroll
28
19
Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
2018 ·Blood ·Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Maria Krevvata, Christopher Chiu, Xiang Qin, (unknown), Sonali Trivedi, Ming Qi, Jesús F. San Miguel
17
20
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts
2014 ·Blood ·Maria Krevvata, Barbara C. Silva, John S. Manavalan, Marta Galán-Díez, Aruna Kode, Brya G. Matthews, David S. Park, Chiyuan A. Zhang, Naomi Galili, Thomas L. Nickolas, David W. Dempster, William C. Dougall, Julie Teruya‐Feldstein, Aris N. Economides, Ivo Kalajzić, Azra Raza, Ellin Berman, Siddhartha Mukherjee, Govind Bhagat, Stavroula Kousteni
101

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan Bladé Breakdown of academic impact, for papers by Luis Palomera Breakdown of academic impact, for papers by Yoshiaki Kuroda Breakdown of academic impact, for papers by María-Ángeles Montalbán Breakdown of academic impact, for papers by Laura Montejano Breakdown of academic impact, for papers by Raquel Jiménez Breakdown of academic impact, for papers by Cara A. Rosenbaum Breakdown of academic impact, for papers by Mihaela Popa McKiver Breakdown of academic impact, for papers by K. Elias Breakdown of academic impact, for papers by Jainulabdeen J. Ifthikharuddin
Rankless by CCL
2026